EDESA BIOTECH, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
EDESA BIOTECH, INC. (EDSA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $25.20 per share for the 9-month period ending 2025-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-12-31 was $0.00.
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4.10, a 72.67% decline from fiscal 2023.
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $15.00, a 128.66% increase from fiscal 2022.
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.56, a 8.97% increase from fiscal 2021.
- EDESA BIOTECH, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $6.02, a 120.51% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $25.20 10-Q · filed 2026-08-13 | ||||
| 2024-09-30 | $4.10 10-K · filed 2025-12-12 | $15.00 10-K · filed 2024-12-13 | |||
| 2024-06-30 | $15.00 10-Q · filed 2025-08-08 | ||||
| 2024-03-31 | $15.55 10-Q · filed 2025-05-14 | ||||
| 2023-09-30 | $15.00 10-K · filed 2025-12-12 | $22.76 10-K · filed 2024-12-13 | |||
| 2023-06-30 | $22.96 10-Q · filed 2024-08-09 | ||||
| 2022-09-30 | $6.56 10-K · filed 2022-12-16 | ||||
| 2022-06-30 | $6.56 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $6.48 10-Q · filed 2022-05-13 | ||||
| 2021-09-30 | $6.02 10-K · filed 2022-12-16 | ||||
| 2021-06-30 | $6.07 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | $6.07 10-Q · filed 2022-05-13 | ||||
| 2020-12-31 | $0.00 10-Q · filed 2021-02-16 | ||||
| 2020-09-30 | $2.73 10-K · filed 2021-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |